CD8A and COVID-19: Using COVID-19 mRNA vaccination (BNT162b2/Comirnaty or mRNA-1273/Spikevax) and SARS-CoV-2 infection as model systems, we analyzed the robustness and longevity of vaccine-induced virus-specific CD4+ and CD8+ T cell immunity in INR versus IR.